Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Live Streamed
On Demand
Back
Favorite
Facebook
Tweet
Print
Cory Hubler, BS
Element Materials Technology/Jones Microbiology Institute
Poster(s):
(P-1059)
In vitro
Activity of Gepotidacin against
Klebsiella pneumoniae
, Including Molecularly Characterized ESBL and Carbapenemase positive Subsets Causing Urinary Tract Infections in the United States (2019-2022)
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1061)
In vitro
Activity of Gepotidacin against
Klebsiella pneumoniae
, Including Molecularly Characterized Fluoroquinolone not Susceptible Subsets Causing Urinary Tract Infections in the United States (2019-2022)
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1085) Characterization of
Enterobacter cloacae
and
Citrobacter freundii
Species Ccomplex Isolates with Decreased Susceptibility to Cephalosporins from United States Hospitals and Activity of Aztreonam-avibactam and Comparator Agents (2019-2023).
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1351) Occurrence of b-lactamases among Enterobacterales isolates from United States Hospitals in a 10-year period: Report from the International Network for Optimal Resistance Monitoring (INFORM) Program
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1360) Activity of Cefiderocol against Carbapenem Non-susceptible Enterobacterales, Including Molecularly Characterized Multidrug-resistant Clinical Isolates, Causing Infections in United States Hospitals (2020–2023)
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1361) Cefiderocol Activity against
Pseudomonas aeruginosa
, Including Resistant Subsets and Isolates Carrying Carbapenemase β-lactamase Genes, from United States Hospitals (2020–2023)
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1362) Cefiderocol Activity against Carbapenem-resistant
Acinetobacter baumannii-calcoaceticus
complex, Including Molecularly Characterized Clinical Isolates, Causing Infections in United States Hospitals (2020–2023)
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1363) Cefiderocol Activity against Clinical Enterobacterales Isolates Carrying Metallo-β-lactamase Genes in United States and European Hospitals (2020–2023)
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT
(P-1364) Cefiderocol Activity against
Pseudomonas aeruginosa
Clinical Isolates Carrying Metallo-β-lactamase Genes in United States and European Hospitals (2020–2023)
Friday, October 18, 2024
12:15 PM – 1:30 PM
US PT